Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Entera Bio Ltd. ENTX

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$42,000
▼ 76.8% YoY
$-11.4M
$-7.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our most advanced product candidate, EB613 (oral teriparatide, or oral PTH[1-34]), is being developed as the first oral, osteoanabolic (bone building) tablet treatment for osteoporosis. EB613 is being developed under a 505(b)(2) application to the listed drug, Forteo® (teriparatide SC injection, Eli Lilly), which was first approved by the FDA in 2002 for the treatment of postmenopausal women with osteoporosis at high risk of fracture and later indicated for men with osteoporosis and osteoporosis associated with sustained systemic glucocorticoid therapy. We have completed a comprehensive nonclinical and clinical package for the EB613 program, including three Phase 1 comparative studies with Forteo® and three Phase 2 clinical studies.

Written from the business description in Entera Bio Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 27 March 2026. Every sentence was checked against that document before publication.

Growth

USD 42,000.00
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -11.4
-5M-10M
202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -27450.0%
-10000%-20000%
202020222025
ROE
FY2025 · ROE -108.0%
-50%-100%
202020222025
Three returns, three denominators.

Each USD of equity lost 108 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -7.5
-5M-10M
202020222025

Total assetsUSD 16.0M
EquityUSD 13.1M
CashUSD 7.1M
Current ratio6.94×

Equity funds 82% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ENTX, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0−0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.25−0.25−0.31−0.45−0.470.67
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−108.0−103.3−80.3−76.2−81.0−105.4
Shares out B0.050.040.040.030.030.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure in 31 reconciliationsAUDITED

Reconciled in 5 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image